---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-016520"
form_type: "8-K"
ticker: null
cik: "0000810509"
company_name: "NAVIDEA BIOPHARMACEUTICALS, INC."
filed_at: "2023-06-05T23:59:59+00:00"
generated_at: "2026-06-14T07:43:26.091401+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Navidea receives NYSE American notice over low stock price; board reshuffled

## Summary
- NYSE American gave until Dec 1, 2023 to cure low price via reverse split or sustained price improvement.
- Entered stock exchange with John K. Scott: 990 Series G preferred shares + $68,853 dividends for 11,969 Series J preferred, subject to approval.
- Director Alexander Cappello resigned; Jill Stefanelli, Ph.D. appointed to Board, effective June 1, 2023.
- Company amended Keystone Capital purchase agreement to cap issuance at 19.99% of shares unless price ≥ greater of book or market value.
- Company remains noncompliant with minimum stockholders' equity requirements from prior NYSE American notices.

## SEC filing metadata
- accession: 0001437749-23-016520
- form_type: 8-K
- cik: 0000810509
- company_name: NAVIDEA BIOPHARMACEUTICALS, INC.
- filed_at: 2023-06-05T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 3.01, 3.02, 1.01, 5.02, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/810509/000143774923016520/0001437749-23-016520-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/810509/000143774923016520/navb20230602_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-016520
- JSON: https://secwatch.observer/filing/0001437749-23-016520.json
- Plain text: https://secwatch.observer/filing/0001437749-23-016520.txt

## Key facts
- Listing & Compliance Notices
  NAVIDEA BIOPHARMACEUTICALS, INC. received a nyse_american deficiency notice notice regarding minimum bid price (rules 1003(f)(v), 1009).
  - Exchange: nyse american
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 1003(f)(v), 1009
  source text: June 1, 2023, the Company received a written notice (the “Notice”) from NYSE Regulation (the “NYSE American”) indicating that the Company is not in compliance with the NYSE American continued listing standard set forth in Section 1003(f)(v) of the NYSE American Company Guide because its shares of Common Stock have been selling for a substantial period of time at a low price per share. The Notice has no immediate effect on the listing or trading of the Company’s Common Stock and the Common Stock will continue to trade on the NYSE American under the symbol “NAVB,” although a “below compliance” i
  evidence_url: https://www.sec.gov/Archives/edgar/data/810509/000143774923016520/0001437749-23-016520-index.htm
- Executive change
  Alexander L. Cappello resigned as Director at NAVIDEA BIOPHARMACEUTICALS, INC..
  - Action: resigned
  - Role: Director
  source text: Effective June 1, 2023, Alexander L. Cappello resigned as a Director of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/810509/000143774923016520/0001437749-23-016520-index.htm
- Executive change
  Jill Stefanelli was appointed as Director at NAVIDEA BIOPHARMACEUTICALS, INC..
  - Action: appointed
  - Role: Director
  source text: The Board appointed Jill Stefanelli, Ph.D. as a Director, effective June 1, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/810509/000143774923016520/0001437749-23-016520-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.